Real-world study of pyrotinib treatment for advanced HER2-positive breast cancer
Part of Cancer, Skin clinical trials.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- At least 18 years old
- Confirmed HER2-positive breast cancer that cannot be surgically removed or has spread
- Either no prior chemotherapy for advanced disease, OR previously treated with taxane and trastuzumab drugs
- Your doctor plans to start you on pyrotinib as your next treatment
- Your medical records from throughout your treatment must be available
- Not currently enrolled in another clinical trial testing investigational drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
This trial tests a new sequence of targeted therapies for advanced HER2-positive breast cancer. It aims to see if giving these drugs in a specific order can shrink tumors and delay progression better than current approaches.
This study tests a combination of two targeted therapies—trastuzumab deruxtecan and pyrotinib—as a first treatment for HER2-positive breast cancer that has spread. The goal is to see if this combination helps shrink tumors or delay progression better than current options.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This study looks at how well the drug pyrotinib works in people with advanced breast cancer that has spread and tests positive for HER2. HER2 is a protein that can make cancer cells grow, and pyrotinib targets it. If you have this type of breast cancer, this study may show if the treatment helps you.
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.